3 years ago

Distinct pattern of TAMs with K65R in patients failing tenofovir-based antiretroviral therapy.

Oliver Ezechi, Oche Agbaji, Emmanuel Idigbe, Jonathan Okpokwu, Adesola Z Musa, Phyllis Jean Kanki, Beth Chaplin, Rosemary Audu, Holly Rawizza, Jay Samuels, Georgina Odaibo, Mohammad Muazu, Chika Onwuamah, Godwin E Imade, Seema Meloni, David O Olaleye
Historically, in HIV patients, the K65R mutation and thymidine analogue mutations (TAMs) have been reported to rarely coexist. We retrospectively reviewed genotype data from paired samples in a cohort of HIV-1-infected Nigerian patients failing first-line antiretroviral therapies containing zidovudine (AZT) or tenofovir (TDF). Samples for each patient were taken at initial confirmed virological failure ≥1000 copies/mL (S1) and then at the latest available sample with viral load ≥1000 copies/mL prior to switch to second-line (S2). Among 103 patients failing AZT, 19 (18.4%) had TAM-1s, 29 (28.2%) TAM-2s, and 21 (20.4%) mixed TAMs by S2. In contrast, in the 87 patients failing TDF, drug resistance mutations at S2 included K65R in 56 (64.4%), TAM-1s in 1 (1.1%), and TAM-2s in 25 (28.7%). Interestingly, 30.4% of patients with K65R in our study developed TAMs. These were exclusively K219E±D67N and were not predicted to confer a resistance cost to future AZT-containing regimens.

Publisher URL: http://doi.org/10.1089/AID.2017.0198

DOI: 10.1089/AID.2017.0198

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.